CA
Carey K. Anders
Highly rated in
9
conditions
Highly rated in
9
conditions
Check Dr. Carey K. Anders' experience treating your condition:
About Dr. Carey K. Anders

Carey Anders is an Oncologist and a Hematologist Oncology expert in Durham, North Carolina. Anders has been practicing medicine for over 21 years and is highly rated in 9 conditions, according to our data. Her top areas of expertise are Triple-Negative Breast Cancer, Metastatic Brain Tumor, Breast Cancer, Brain Tumor, and Gamma Knife Radiosurgery. She is licensed to treat patients in North Carolina. Anders is currently accepting new patients.

Her clinical research consists of co-authoring 128 peer reviewed articles and participating in 21 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Carey K. Anders it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Carey K. Anders accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
  •  Cigna
  •  UnitedHealthcare
  •  Aetna

Call to see if your plan is accepted.
Locations
20 Duke Medicine Cir, Durham, NC 27710
Background & Education
Graduate Institution
Other, 2002
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Duke Raleigh Hospital
Languages Spoken
English
Arabic
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


21 Clinical Trials

AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
LCCC 1642: Plasma Circulating Tumor DNA (ctDNA) Analyses in ER+ Metastatic Breast Cancer
LCCC 1410: Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
View 16 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors